DENDRITIC CELL BASED IMMUNOTHERAPY IN RECURRENT AND METASTATIC ADVANCED SOLID TUMORS SHOWING EXCELLENT RESPONSE: THREE CASE STUDIES
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 4, Pages 1753-1761
AbstractBackground: Despite conventional treatment approaches for cancers, relapsed and metastatic refractory cancers have overall poor prognosis with poor quality of life. Dendritic Cell (DC) - based immunotherapy is a viable and promising treatment option in such cases. Dendritic Cell Therapy (DCT) induces antitumor T-cell response in-vivo.
Case Series : We describe three of the ten cancer cases of patients who despite being successfully treated by conventional treatment had disease recurrence with multiple metastases and disease progression. In the first case, a 17 year male patient who is a known case of osteosarcoma of right femur who had undergone successful conventional treatment had a recurrence with bilateral lung metastases. The second case is a 64 year female patient who is a known case of Metastatic adenocarcinoma of unknown primary with metastases at diagnosis who despite being treated by conventional treatmenT had disease progression. The third case is a case of 47 year female patient who is a known case of Non-small cell Lung cancer who was treated successfully by conventional treatment had a recurrence with multiple metastases. All the three cases were advised further treatment by Dendritic Cell therapy.
Results: One of three patients has shown complete response and remaining two patients has shown partial response with longer survival and improvement in quality of life.
Conclusion: Dendritic cell based Immunotherapy can activate antitumoral T cell responses in patients with various cancers. This data indicates that treatment with autologous tumor-pulsed DCs is safe and can activate tumor specific cellular cytotoxicity. Clinical responses can be achieved even in patients with metastatic and advance stage cancer.
- Article View: 138
- PDF Download: 95